ADC - Vincerx gains as FDA clears trial for blood cancer candidate
2023-08-22 08:50:28 ET
More on Vincerx
- Vincerx Pharma discloses departure of medical chief
- Vincerx Pharma GAAP EPS of -$0.79 misses by $0.03
- Vincerx Pharma climbs 4% on insider buying
- Vincerx Pharma's VIP152 an Orphan Drug in Europe for large b-cell lymphoma
- Seeking Alpha’s Quant Rating on Vincerx Pharma
For further details see:
Vincerx gains as FDA clears trial for blood cancer candidate